Literature DB >> 16938192

[Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study].

J Iñigo1, J M Sendra, R Díaz, C Bouza, A Sarría-Santamera.   

Abstract

BACKGROUND AND
OBJECTIVE: Severe sepsis is a complex syndrome to define, diagnose and treat. This population-based study describes the epidemiology of sepsis in the Region of Madrid, estimates its incidence and mortality, and assesses its impact on hospital stays and costs. PATIENTS AND METHODS: The source of information was the Minimum Basic Hospital Data Set from the Region of Madrid in 2001. Severe sepsis cases were defined as discharges with a combination of organic failure and presence or suspicion of infection through a combination of codes previously proposed and utilized. A descriptive study was performed, incidence rates were calculated, lengths of stay and costs were estimated, and mortality was analyzed.
RESULTS: 6,968 episodes were identified. Mean age was 62.5 year. 59.7% were male. Annual incidence was 14.1/10,000 inhabitants, being highest for those 84 and older (230.8/10,000). 1.7 infections per episode were detected. More frequently identified microorganisms were Streptococcus sp., Staphylococcus sp., Escherichia coli and Candida sp. The most frequent organic dysfunctions were renal (39.7%) and respiratory (35.7%). Mortality was 33%. Mortality was higher in cases with more than one organic failure, hepatic dysfunction or cancer. Mean length of stay was 28.9 day. Annual overall costs were 70 million euros.
CONCLUSIONS: Severe sepsis is a frequent process, with a high mortality and a significant impact on health care resource utilization.

Entities:  

Mesh:

Year:  2006        PMID: 16938192     DOI: 10.1016/s0210-5691(06)74507-7

Source DB:  PubMed          Journal:  Med Intensiva        ISSN: 0210-5691            Impact factor:   2.491


  7 in total

Review 1.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Christian Gluud; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

2.  Trends in hospitalizations of patients with sepsis and factors associated with inpatient mortality in the Region of Madrid, 2003–2011.

Authors:  O H Ayala-Ramírez; M F Domínguez-Berjón; M D Esteban-Vasallo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03       Impact factor: 3.267

3.  Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain.

Authors:  David Suarez; Ricard Ferrer; Antonio Artigas; Izaskun Azkarate; José Garnacho-Montero; Gemma Gomà; Mitchell M Levy; Juan Carlos Ruiz
Journal:  Intensive Care Med       Date:  2010-12-09       Impact factor: 17.440

4.  Epidemiology and recent trends of severe sepsis in Spain: a nationwide population-based analysis (2006-2011).

Authors:  Carmen Bouza; Teresa López-Cuadrado; Zuleika Saz-Parkinson; José María Amate-Blanco
Journal:  BMC Infect Dis       Date:  2014-12-21       Impact factor: 3.090

5.  Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting.

Authors:  Juan Carlos Yébenes; Juan Carlos Ruiz-Rodriguez; Ricard Ferrer; Montserrat Clèries; Anna Bosch; Carol Lorencio; Alejandro Rodriguez; Xavier Nuvials; Ignacio Martin-Loeches; Antoni Artigas
Journal:  Ann Intensive Care       Date:  2017-02-20       Impact factor: 6.925

6.  Trends in mortality in septic patients according to the different organ failure during 15 years.

Authors:  Carolina Lorencio Cárdenas; Juan Carlos Yébenes; Emili Vela; Montserrat Clèries; Josep Mª Sirvent; Cristina Fuster-Bertolín; Clara Reina; Alejandro Rodríguez; Juan Carlos Ruiz-Rodríguez; Josep Trenado; Elisabeth Esteban Torné
Journal:  Crit Care       Date:  2022-10-03       Impact factor: 19.334

Review 7.  [Automatic detection of bacterial and fungal infections in blood].

Authors:  José Miguel Molina; Juan Córdoba; Paula Ramírez; Miguel Gobernado
Journal:  Enferm Infecc Microbiol Clin       Date:  2008-07       Impact factor: 1.731

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.